From these DEGs, we found studies in the context of MS for only three of them (RMRP, EDIL3 and GSTM1), but, interestingly, the existing studies describe a differential expression of these genes in MS patients compared to HDs, suggesting their potential use as disease biomarkers [25,26,27]. Here, GSTM1 is linked to myeloid sarcoma.